Georgia Expands Access to Medical Cannabis

ATLANTA – A revised medical Cannabis law takes effect in Georgia on Wednesday, broadening the conditions that qualify patients for legal access and permitting vaporization as an approved method of use for the first time.

The measure, Senate Bill 220, known as the Putting Georgia’s Patients First Act, was signed by Gov. Brian Kemp in May after passing both chambers of the General Assembly with bipartisan support. The law replaces the state’s “low-THC oil” terminology with “medical cannabis” and renames the patient registry to match.

Among the changes, lupus and intractable pain join the list of qualifying conditions, while inflammatory bowel disease replaces the narrower Crohn’s disease category. Cancer eligibility now extends to nearly all forms of the disease apart from non-metastatic skin cancer, and HIV-related qualification shifts to recognize Stage III diagnoses rather than AIDS specifically. Several existing conditions, including ALS, multiple sclerosis, Parkinson’s disease, sickle cell disease, Tourette’s syndrome and Alzheimer’s disease, no longer require classification as severe or end-stage for a patient to qualify.

The law also resets how much medical Cannabis a registered patient may legally hold. In place of the previous 20-fluid-ounce limit on low-THC oil, patients can now possess products totaling up to 12,000 milligrams of THC, provided they remain in labeled pharmaceutical packaging, with individual packages capped at 1,200 milligrams.

One of the more closely watched provisions allows patients 21-plus to use medical Cannabis through vaporization, including dry-herb devices, while smoking or combustion remains prohibited and public consumption stays barred under any method. Gary Long, CEO of Botanical Sciences, one of the state’s largest dispensary operators, told that inhalation offers patients faster relief than the oils and tinctures already sold under the program.

The Georgia Access to Medical Cannabis Commission has until January 1, 2027, to finalize testing and labeling standards for higher-potency and vapor products, so the full range of newly permitted items may take additional time to reach dispensary shelves. Out-of-state patients gain a separate benefit: the law recognizes their existing medical Cannabis credentials for up to 45 days without establishing Georgia residency.

At the signing, Kemp said he does not regard the medical access expansion as a step toward recreational legalization in the state. Georgia’s program has long been considered among the most restrictive in the country; the framework authorized in 2019 did not become operational until 2023.

Tracking how conservative states approach cannabis reform, Highly Capitalized Network-HCN finds Georgia’s update a useful reference point. The expanded condition list and higher possession limit widen the pool of patients with legal access, while the addition of vaporization brings the state’s program a step closer to more established medical markets. The extent of that expansion in practice will likely come down to how quickly licensed pharmacies and producers can supply new product formats once regulators finish the remaining rules.